C. Lerchenmueller

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

Beate Rau, Hauke Lang, Alfred Koenigsrainer et al. · Journal of Clinical Oncology · 2023 · 128 citations · Full text

Medicine, Oncology, Surgery +13

Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population

Sebastian Stintzing, Dominik Paul Modest, Ludwig Fischer von Weikersthal et al. · Annals of Oncology · 2014 · 63 citations · Full text

Medicine, Oncology, Radiology +16

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Marlies Michl, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al. · Annals of Oncology · 2016 · 42 citations

Medicine, Oncology, Pharmacology +16

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

Anja Welt, Norbert Marschner, C. Lerchenmueller et al. · Breast Cancer Research and Treatment · 2016 · 24 citations · Full text

Medicine, Oncology, Pharmacology +14